| Literature DB >> 26938980 |
Andreas Schmitt1,2, André Reimer1,2, Norbert Hermanns1,2,3, Jörg Huber4, Dominic Ehrmann1, Sabine Schall1, Bernhard Kulzer1,2,3.
Abstract
AIM: To appraise the Diabetes Self-Management Questionnaire (DSMQ)'s measurement of diabetes self-management as a statistical predictor of glycaemic control relative to the widely used SDSCA.Entities:
Mesh:
Substances:
Year: 2016 PMID: 26938980 PMCID: PMC4777391 DOI: 10.1371/journal.pone.0150774
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Fig 1Stuctural equation model of diabetes self-management as measured by the DSMQ and glycaemic control for patients with type 1 and type 2 diabetes.
Data are standardised regression weights (β) for paths or squared multiple correlations (R2) for variables. Boxes indicate manifest measurement variables; ovals indicate latent variables operationalised by manifest indicators; error terms are not displayed for ease of presentation. SRMR, Standardised Root Mean Square Residual; TLI, Tucker Lewis Index; CFI, Comparative Fit Index; RMSEA, Root Mean Square Error of Approximation. Indication of two-sided significance: * P < 0.05; † P < 0.01; ‡ P < 0.001.
Fig 2Stuctural equation model of diabetes self-management as measured by the SDSCA and glycaemic control for patients with type 1 and type 2 diabetes.
Data are standardised regression weights (β) for paths or squared multiple correlations (R2) for variables. Boxes indicate manifest measurement variables; ovals indicate latent variables operationalised by manifest indicators; error terms are not displayed for ease of presentation. SRMR, Standardised Root Mean Square Residual; TLI, Tucker Lewis Index; CFI, Comparative Fit Index; RMSEA, Root Mean Square Error of Approximation. Indication of two-sided significance: * P < 0.05; † P < 0.01; ‡ P < 0.001.
Characteristics of the study sample.
| Total sample | Type 1 DM | Type 2 DM | |
|---|---|---|---|
| Female gender | 233 (54.2%) | 149 (60.1%) | 84 (46.2%) |
| Age (years) | 46.6 ± 14.6 | 39.0 ± 13.2 | 57.0 ± 8.9 |
| BMI (kg/m2) | 30.0 ± 10.0 | 26.9 ± 11.0 | 34.1 ± 6.6 |
| Diabetes duration (years) | 15.3 ± 10.5 | 16.6 ± 12.1 | 13.5 ± 7.5 |
| Diabetes treatment: | |||
| Insulin treatment | 393 (91.4%) | 248 (100%) | 146 (80.2%) |
| Other medical treatment | 37 (8.6%) | 0 (0%) | 36 (19.8%) |
| HbA1c: | |||
| Value in % | 8.5 ± 1.6 | 8.5 ± 1.6 | 8.6 ± 1.5 |
| Value in mmol/mol | 70 ± 17 | 70 ± 18 | 70 ± 17 |
| Patients with values > 7.5% (59.5mmol/mol) | 308 (71.6%) | 176 (71.0%) | 132 (72.5%) |
| Long-term complications: | |||
| Retinopathy | 100 (23.3%) | 57 (23.0%) | 43 (23.6%) |
| Neuropathy | 123 (28.6%) | 36 (14.5%) | 87 (47.8%) |
| Nephropathy | 44 (10.2%) | 11 (4.4%) | 33 (18.1%) |
| Foot ulcer | 23 (5.3%) | 5 (2.0%) | 18 (9.9%) |
Data are n (%) or M ± SD. BMI, Body Mass Index; HbA1c, glycated haemoglobin; M, mean; SD, standard deviation.
a oral antidiabetic agents and/or incretin mimetics.